Pulmonary exacerbations in cystic fibrosis: It's time to be explicit!

American Journal of Respiratory and Critical Care Medicine

Volumn 169, Issue 7, 2004, Pages 781-782

  Marshall, Bruce C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE EXACERBATION; EDITORIAL; GRAM NEGATIVE INFECTION; HUMAN; LUNG FUNCTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ADULT; ANTI-BACTERIAL AGENTS; CANADA; CHRONIC DISEASE; CYSTIC FIBROSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 1642488950     PISSN: 00030805     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. Aaron SD, Ramotar K, Ferris W, Vandemheen K, Saginur R, Tullis E, Haase D, Kottachchi D, St. Denis M, Chan F. Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2004;169:811-815.
2. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey B. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139:359-365.
3. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-352.
4. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121:64-72.
5. Lieu TA, Ray GT, Farmer G, Shay GF. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999;103:e72.
6. Parsek MR, Singh PK. Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol 2003;57:677-701.
7. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, Hiatt P, McCoy K, Castile R, Smith AL, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001;183:444-452.
8. Cystic Fibrosis Foundation. Clinical practice guidelines for cystic fibrosis. Bethesda, MD: Cystic Fibrosis Foundation; 1997.
9. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141:914-921.
10. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003;123:1495-1502.
11. Saiman L, Mehar F, Niu WW, Neu HC, Shaw KJ, Miller G, Prince A. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996;23:532-537.
12. Lang BJ, Aaron SD, Ferris W, Hebert PC, MacDonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2000;162:2241-2245.
13. Aaron SD, Ferris W, Ramotar K, Vandemheen K, Chan F, Saginur R. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J Clin Microbiol 2002;40:4172-4179.
14. Dakin C, Henry RL, Field P, Morton J. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol 2001;31:436-442.